SARS-CoV-2 infection in hospitalized children with type 1 and type 2 diabetes

Connie Trieu a,⁎, Bhuvana Sunil b, Ambika P. Ashraf b, Joshua Cooper a, April Yarbrough c, Swetha Pinninti a, Suresh Boppana a,⁎, Ambika P. Ashraf a,⁎, Bhuvana Sunil a,⁎, Suresh Boppana a,⁎, Joshua Cooper a, April Yarbrough c

a Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, United States of America
b Department of Pediatrics, Division of Pediatric Endocrinology, University of Alabama at Birmingham, Birmingham, AL, United States of America
c Department of Pharmacy, Children’s of Alabama, Birmingham, AL, United States of America
d Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States of America

⁎ Corresponding author at: Children’s Harbor Building 308, 1600 6th Avenue South, Birmingham, AL 35233, United States of America.
E-mail address: ctrieu@peds.ufl.edu (C. Trieu).

https://doi.org/10.1016/j.jcte.2021.100271
Received 2 March 2021; Received in revised form 11 October 2021; Accepted 22 October 2021
Available online 28 October 2021
2214-6237/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.

ARTICLE INFO

Keywords: COVID-19 Diabetes mellitus Diabetic ketoacidosis

ABSTRACT

Context: While diabetes is a risk factor for severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults, there is conflicting data surrounding the relationship between the virus and diabetic disease process in children.

Objective: This case series aims to illustrate an increase in the incidence of types 1 and 2 diabetes mellitus (T1DM, T2DM) between April – November 2020 at a large tertiary care children’s hospital and examine the characteristics and adverse outcomes in these children. In addition, two children with significant complications from coronavirus disease 2019 (COVID-19) and diabetes are highlighted.

Methods: Hospitalized children with T1DM or T2DM and SARS-CoV-2 infection were identified, and electronic medical records were reviewed.

Results: We observed a 16.3% increased rate of new-onset T1DM and 205.3% increased rate of new-onset insulin-dependent T2DM between April and November 2020 compared to the same observational time frame in 2019. Among children with new-onset T1DM, 56.9% presented with DKA in 2019 and 47.1% in 2018 compared to 64.3% in 2020, which was higher than the national average. Twenty-eight children were diagnosed with COVID-19 and diabetes during this time. The 2 described cases with significant complications from COVID-19 and DKA required large doses of intravenous insulin over a prolonged duration.

Conclusion: This study highlights that the COVID-19 pandemic might have led to an increased rate of new-onset T1DM, T2DM, and DKA in children and adolescents compared to a similar time frame in the prior 2 years. The clinical phenotypes and outcomes in children with diabetes to COVID-19 infection may be distinct and therefore, future pediatric specific studies are needed to define the role of SARS-CoV-2.

Introduction

As the coronavirus disease 2019 (COVID-19) pandemic continues affecting > 188 countries/territories around the globe, new associations between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] and other pediatric disease processes are being reported. The diabetogenic effect of the novel coronavirus is being debated, both with its ability to worsen metabolic complications of Type 1 diabetes mellitus (T1DM), including diabetic ketoacidosis (DKA), which is characterized by hyperglycemia, ketosis, and metabolic acidosis. Several reports suggest that this effect may be beyond the well-studied triggers from other viral illnesses [2–5]. A study from Germany suggested an increase in DKA at diabetes diagnosis among patients with COVID-19 [6]. However, other reports fail to demonstrate this association [7,8]. The role of SARS-CoV-2 on type 2 diabetes (T2DM) incidence in children and complications in children with known T2DM has also not been well described. This study aims to illustrate the increased occurrence of new-onset T1DM and T2DM between April to November 2020, compared to the same observational time frames in the previous 2 years, at a tertiary care children’s hospital in the state of Alabama with a large referral base. We also describe the characteristics and outcomes of children...
admitted with T1DM or T2DM during the months of April to November 2020 with SARS-CoV-2 infection in order to identify possible factors underlying this trend in increased occurrence and highlight two key cases of T1DM and T2DM whose clinical courses were complicated by COVID-19 to illustrate differences in management strategies.

Materials and methods

With a hospital-wide policy of screening all admissions for COVID-19 on April 27, 2020, hospitalized children with SARS-CoV-2 infection were identified and enrolled into a natural history study approved by the Institutional Review Board (IRB) for Human Use, and informed consent was obtained. Nasopharyngeal (NP) samples were analyzed by reverse transcription polymerase chain reaction (RT-PCR), and viral loads were determined by generating a standard curve based on dilutions of known SARS-CoV-2 genomic RNA obtained from the World Reference Center for Emerging Viruses and Arboviruses, with a limit of detection between 600 and 800 copies/mL [9]. The International Classification of Diseases tenth revision – Clinical Modification (ICD-10-CM) diagnosis codes E10.9, E10.10, E10.65, E11.0, E11.10, E11.65 and E11.9 were used to identify all potentially eligible patients (ICD-10-CM) diagnosis codes E10.9, E10.10, E10.65, E11.0, E11.10, E11.65 and E11.9 were used to identify all potentially eligible patients with a physician-ascertained diagnosis of T1DM or T2DM from April-November for the years 2018–2020. For T1DM, an overall annual trend in increased incidence is seen between April – November 2020 with 286 children admitted with new-onset T1DM when compared to 246 children in 2019, a 16.3% increase. This contrasts with the same observational time frame in the year prior, during which a 6.5% yearly decrease was seen from 2018 to 2019. A considerable increase in the number of children with T1DM who presented with DKA during the period between April and November 2020 was seen, representing 64.3% compared to 56.9% in 2019 and 47.1% in 2018. A more significant increase in T2DM (205.3%) was seen from April - November 2020 with 290 children hospitalized with new-onset T2DM, compared to 95 children during the same time frame in 2019 and 88 children in 2018. Of the children admitted with new-onset T2DM, 59.3% presented with DKA, compared to 4.2% in 2019 and 5.7% in 2018. Fig. 1 represents the trends of new-onset T1DM admissions by month, comparing annual trends from 2018 to 2020. The demographic, clinical, and laboratory characteristics of all patients with either T1DM or T2DM and SARS-CoV-2 infection are shown in Table 1.

Twenty-eight children were hospitalized with diabetes and COVID-19 between April – November 2020. Of the children admitted with a T1DM diagnosis, 21 tested positive for SARS-CoV-2 RNA by RT-PCR of NP swabs. SARS-CoV-2 viral loads for these children ranged from 1.46 x 10^8 to 1.07 x 10^9 copies/mL. The majority (16/18 or 89%) of these children did not have significant pulmonary disease regardless of the severity of their DKA, nor did higher viral loads predict or correlate with the severity of DKA. Tables 2 and 3 represent the demographic, clinical, and laboratory characteristics of patients with new-onset or preexisting T1DM and SARS-CoV-2 infection. The majority (89% and 75%, respectively) of children with new-onset or preexisting T1DM and COVID-19 presented with DKA (Tables 2 and 3). Of these, one child had severe DKA and COVID-19, and his management has been elaborated below.

Results

Fig. 1 illustrates the number of admissions for new onset T1DM from April to November 2020 at Children’s of Alabama. For T1DM, an overall annual trend in increased incidence is seen between April – November 2020 with 286 children admitted with new-onset T1DM when compared to 246 children in 2019, a 16.3% increase. This contrasts with the same observational time frame in the year prior, during which a 6.5% yearly decrease was seen from 2018 to 2019. A considerable increase in the number of children with T1DM who presented with DKA during the period between April and November 2020 was seen, representing 64.3% compared to 56.9% in 2019 and 47.1% in 2018. A more significant increase in T2DM (205.3%) was seen from April - November 2020 with 290 children hospitalized with new-onset T2DM, compared to 95 children during the same time frame in 2019 and 88 children in 2018. Of the children admitted with new-onset T2DM, 59.3% presented with DKA, compared to 4.2% in 2019 and 5.7% in 2018. Fig. 1 represents the trends of new-onset T1DM admissions by month, comparing annual trends from 2018 to 2020. The demographic, clinical, and laboratory characteristics of all patients with either T1DM or T2DM and SARS-CoV-2 infection are shown in Table 1.
loads ranged from 8.28 × 10\(^{-2}\) to 3.82 × 10\(^{2}\) copies/mL. The levels of SARS-CoV-2 viral load between children with T1DM and T2DM did not differ significantly, nor did it differ between children with new-onset diabetes and those with pre-existing diabetes. Four of the children with T2DM had a recent HbA1C of ≥ 8.5% (69.4 mmol/mol), meeting the American Diabetes Association 2020 (ADA) recommendations for insulin initiation. One child with T2DM and COVID-19 had a presentation complicated by severe mixed DKA and HHS, and his management has been elaborated below.

### Case A: T1DM with DKA, COVID-19 and complications

An 8-year-old White male with established T1DM diagnosed in 2014 presented to his local emergency department with 3 days of emesis and labored respirations. Laboratory evaluation revealed a serum glucose 442 mg/dL, pH 6.77, and bicarbonate 2.2 mmol/L, consistent with a diagnosis of severe DKA. He received intravenous fluids for volume repletion and was started on a continuous insulin infusion at 0.15 unit/kg/hour. He remained significantly acidic with pH values ranging between 6.7 and 6.9 for the next 6 h, requiring a bicarbonate infusion for the worsening mixed acidosis. His anion gap corrected 12 h after initiation of insulin therapy.

Shortly after arrival to the emergency department, the patient became hypoxic and tested positive for SARS-CoV-2 by RT-PCR. Chest x-ray showed bilateral infiltrates, and his oxygen requirement quickly escalated requiring intubation. The patient was started on remdesivir 5 mg/kg intravenously (IV) followed by 2.5 mg/kg IV daily and dexamethasone 0.15 mg/kg IV daily for his severe COVID-19. Initial echocardiogram revealed an ejection fraction of 42%, which improved to 50% two days later. He then developed pulmonary edema and worsening renal dysfunction refractory to diuretics, and he was transferred to our institution on hospital day 3 for dialysis.

Vital signs upon transfer included a temperature 36.1 °C, heart rate 139 beats per minute, respiratory rate 22 breaths per minute, blood pressure 96/51 mmHg, and oxygen saturation 96% on mechanical ventilation. Physical examination was notable for anasarca, and he soon progressed to hemodynamic instability requiring 3 vasopressors. He was started on continuous renal replacement therapy (CRRT) the following day for acute renal failure, and remdesivir was discontinued due to decreased renal clearance. With severe COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), and the potential for poor subcutaneous absorption in the presence of systemic inflammation, the patient was continued on a prolonged insulin drip for 16 days for management of his hyperglycemia. CRRT was discontinued after 10 days, and his renal function recovered. He was extubated 13 days after transfer to our hospital and was subsequently weaned to room air 9 days later. The patient was hospitalized for a total of 36 days, and SARS-CoV-2 RNA remained detectable from his upper respiratory tract throughout his hospitalization.

### Case B: T2DM with DKA, COVID-19 and complications

A 15-year-old Black male with a new diagnosis of T2DM presented with progressive myalgia, fatigue, several days of polydipsia, and altered mental status to the emergency room. He had a body weight of 90 kg and BMI of 37.5 kg/m\(^2\). He was hypertensive (168/98 mmHg), tachycardic to 140 beats per minute, tachypneic with a respiratory rate > 35 breaths per minute, and hypoxic (oxygen saturation, 88%) upon presentation. Laboratory evaluation revealed a serum glucose of 2238 mg/dL, pH 7.18, bicarbonate 9 mmol/L, serum osmolarity of 401 mOsm/L - consistent with a diagnosis of mixed DKA and HHS. The patient had concomitant lactic acidosis, severe dehydration with a BUN...
**Table 2**
Demographic, Clinical and Laboratory Characteristics of Patients with New-Onset T1DM and SARS-CoV-2 Infection.

| Variable                                 | Case 1* | 2    | 3    | 4    | 5** | 6    | 7    | 8    | 9    |
|------------------------------------------|---------|------|------|------|------|------|------|------|------|
| Age (years)                              | 12      | 11   | 13   | 14   | 12   | 8    | 13   | 3    | 9    |
| Gender                                   | Male    | Female | Male | Female | Male | Black | Black | Female | White |
| Race/ethnicity                           | White   | Black | White | Black | Black | Black | Black | White | Black |
| BMI (kg/m²)                              | 18.6    | 28.4  | 18.2  | 16.8  | 16.9  | 11.9  | 15.6  | 15.2  | 12   |
| BMI z score                              | +0.10   | +2.10 | +0.39 | -1.21 | -0.68 | -3.99 | -1.57 | -0.3  | -3.9  |
| Comorbidities                            | Asthma  | Obesity | None | None | Vitamin D deficiency | Asthma | None | H3F3A mutation, developmental delay, epilepsy, dysphagia | None |
| Reason for admission                     | NOD | NOD, DKA | NOD, DKA | NOD, DKA | NOD, DKA | NOD, DKA | NOD, DKA | NOD, DKA | NOD, DKA |
| Glutamic acid decarboxylase antibody     | –       | +    | +    | +    | –    | +    | +    | +    | +    |
| Inlet cell antibody                      | –       | –    | –    | –    | –    | –    | –    | –    | –    |
| Other autoantibodies                     | Negative IA-2 and ZnTr8 | Negative IA-2 and ZnTr8 | NA | NA | Positive IA-2 and ZnTr8 | Negative IA-2 and ZnTr8 | NA | NA | Negative ZnTr8 | NA |
| Hemoglobin A1C (%) at presentation       | >14.0   | 13.2  | >14.0 | 10.6  | >14.0 | >14.0 | >14.0 | 7.9  | >14.0 |
| SARS-CoV-2 viral load (copies/mL)        | 1.24x10⁶⁺ | 4.41x10⁴⁺ | NA | 9.28x10⁵⁺ | NA | 1.07x10⁸⁺ | 1.67x10²⁺ | 9.47x10⁶⁺ | 1.46x10⁵⁺ |
| Severity of diabetic ketoacidosis        | None    | Mild  | Mild  | Severe | Moderate | Moderate | Moderate | Mild | Severe |
| Initial venous blood gas pH              | 7.36    | 7.27  | 7.27  | 7.01  | 7.14  | 7.11  | 7.30  | 7.22  | 6.85  |
| Serum bicarbonate (mmol/L)               | 21      | 14    | 13    | 6     | <5    | 6     | 13    | 10    | <5    |
| Serum glucose (mg/dL)                    | 372     | 216   | 290   | 642   | 367   | 397   | 427   | 1134  | 482   |
| Urine ketones                            | 2⁺      | 3⁺    | 2⁺    | 2⁺    | 4⁺    | 2⁺    | 3⁺    | 2⁺    | 4⁺    |

*Case 1 was negative for autoantibodies that are usually present in Type 1 diabetes mellitus (T1DM). Nevertheless, a diagnosis of antibody-negative T1DM was made given the normal BMI, absence of acanthosis nigricans and a strong family history of T1DM in multiple first-degree relatives, including mother and maternal grandfather.

**Case 5 was also negative for autoantibodies that are usually present in T1DM. A diagnosis of antibody-negative T1DM was made given normal BMI, lack of acanthosis nigricans and a strong family history of autoimmune diabetes.**

*Abbreviations: BMI = Body mass index; SARS-CoV-2 = Severe acute respiratory syndrome coronavirus 2; T1DM = Type 1 diabetes mellitus; NA = Not available; IA-2 = Insulinoma antigen 2 antibodies; ZnTr8 = Zinc transporter 8 antibodies; NOD = New-onset diabetes; DKA = Diabetic ketoacidosis.*

Increased rates of new-onset diabetes: Limited data to date reports an increase in the number of new-onset T1DM and DKA cases in the United Kingdom [14] and Germany [6], but a decrease was seen in Italy [7,15] and India [8] during the early period of the pandemic. With increased rates of new-onset T1DM and T2DM pediatric admissions in 2020 at our institution, these findings are consistent with studies suggesting an increased occurrence of new-onset T1DM that may be precipitated by COVID-19 [16]. Even though there have been reports on COVID-19 and T1DM in children [11], the data on T2DM in children have been sparse. Interestingly, we found an increase in the number of admissions for new-onset diabetes, particularly T2DM (205.3% increase), during the months of April through November 2020, compared to previous years, at our institution. This is significantly increased from the trends reported by SEARCH for Diabetes in Youth Study from 2002 to 2015, during which time the annual percentage changes in T1DM and T2DM incidences were 1.9% per year and 4.8% per year, respectively [17]. Globally, the average increase in T1DM incidence is 3–4% per year [18]. We also found an increased incidence of DKA in our new-onset T1DM population when compared to overall nationwide averages in children.

Discussion

Through this case series, we describe 28 pediatric patients within an 8-month period with concurrent SARS-CoV-2 infection and metabolic complications from type 1 or type 2 diabetes. It is important to recognize that patients with uncontrolled T1DM or T2DM are at risk for severe illness from SARS-CoV-2 infection. Our report shows a potential association between SARS-CoV-2 and poor glycemic control resulting in DKA, and this is worrisome because poor glycemic control is fairly common in the pediatric diabetes population, with < 50% of children achieving HbA1C ≤ 7.5% (58.5 mmol/mol) across the world [10]. Furthermore, the two highlighted cases suggest that management of hyperglycemia may be difficult [11] during severe illness from SARS-CoV-2 infection. Such severity, although less commonly seen in children, has been reported throughout the U.S. and Canada, with higher rates of severe DKA seen during the COVID-19 pandemic [12,13].
### Table 3
Demographic, Clinical and Laboratory Characteristics of Patients with Preexisting T1DM and SARS-CoV-2 Infection.

| Variable                              | Case 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---------------------------------------|--------|---|---|---|---|---|---|---|---|----|----|----|
| Age (years)                           | 17     | 10 | 15 | 17 | 15 | 5 | 13 | 16 | 15 | 5   | 8   | 5  |
| Gender                                | Female | Female | Male | Female | Male | Male | Female | Male | Female | Male | White | White |
| Race/ethnicity                        | Black  | Hispanic | Black | Black | Hispanic | Black | Black | Black | Black | White | White | White |
| BMI (kg/m²)                           | 32.8   | 22.8 | 24.1 | 23.1 | 25.7 | 15.7 | 20.4 | 24.1 | 22.9 | 26.3 | 17.1 | 15.5 |
| BMI z score                           | +1.9   | +1.82 | +1.01 | +0.6 | +1.80 | +0.23 | +0.55 | +1.01 | +1.22 | +1.34 | +1.16 | -0.05 |
| Comorbidities                         | Obesity, depression, anxiety | None | Overweight | None | Overweight | Microalbuminuria | None | Bipolar disorder, ADHD | ADHD | PCOS, depression | Dehydration | None |
| Reason for admission                  | Diabetes education | DKA | DKA | DKA | DKA | DKA | DKA | DKA | DKA | Suicidal ideation | IV rehydration | DKA |
| Duration of Type 1 diabetes mellitus  | <1 year | 1 year | 3 years | 8 years | 4 years | 4 years | 4 years | 4 years | 4 years | 4 years | 4 years | 6 years |
| Glutamic acid decarboxylase antibody  | +       | +       | +       | +       | +       | +       | +       | +       | +       | +       | +       | +       |
| Islet cell antibody                   | –       | –       | –       | –       | –       | –       | –       | –       | NA      | NA      | NA      | NA      |
| Other autoantibodies                  | NA     | NA     | NA     | NA     | NA     | IA-2NA and positive ZnTr8 | Positive IA-2 and ZnTr8 | Positive IA-2 and ZnTr8 | NA      | NA      | IA-2NA and negative ZnTr8 |
| Hemoglobin A1C (%) in 2019            | –      | 9      | 13.7   | 7.7   | >14.0   | 12.7   | >14.0   | >14.0   | 8.2     | 12.4   | 9.5     | >14.0   |
| Hemoglobin A1C (%) at presentation in 2020 | 8.8 | 10.1 | >14.0 | 8.2 | >14.0 | 13.1 | >14.0 | >14.0 | 7.6 | 11.1 | 9.7 | >14.0 |
| SARS-CoV-2 viral load (copies/mL)     | 1.89x10^3 | 1.59x10^7 | 5.48x10^2 | 9.67x10^2 | 1.46x10^3 | 4.65x10^4 | 4.10x10^5 | 3.74x10^6 | 1.51x10^7 | 1.09x10^8 | 2.83x10^5 | 5.54x10^5 |
| Severity of diabetic ketoacidosis     | None   | Mild   | Severe | Mild   | Moderate | Moderate | Mild   | Mild   | None   | Severe | None   | Severe |
| Initial venous blood gas pH           | 7.38   | 7.23   | 7.04   | 7.25   | 7.20   | 7.10   | 7.29   | 7.30   | –      | 7.00   | 7.43   | 6.77   |
| Serum bicarbonate (mmol/L)            | 20     | 8      | 6      | 11     | 14     | 14     | 16     | 11     | <5     | 14     | 2.2    |
| Serum glucose (mg/dL)                 | 119    | 314    | 478    | 203    | 535    | 338    | 430    | 511    | 65     | 299    | 356    | 442    |
| Urine ketones                         | NA     | 4+     | 3+     | 2+     | 3+     | 2+     | 1+     | +      | –      | –      | +      | NA     |

Abbreviations: BMI = Body mass index; SARS-CoV-2 = Severe acute respiratory syndrome coronavirus 2; NA = Not available; IA-2 = Insulinoma antigen 2 antibodies; ZnTr8 = Zinc transporter 8 antibodies; ADHD = attention deficit hyperactivity disorder; PCOS = polycystic ovarian syndrome; DKA = diabetic ketoacidosis.
new-onset diabetes, which average around 30% [19], which is in accordance with several other studies [6,12,13]. Our report also highlights the need for further investigation into the potential diabetogenic effect of COVID-19. There are several proposed mechanisms for new-onset diabetes during SARS-CoV-2 infection - whether the diabetes originated from the infection, or the infection triggered autoimmunity. The novel coronavirus enters host cells by binding to angiotensin-converting enzyme 2 (ACE2), a transmembrane glycoprotein with proteolytic activity that can be found expressed on many tissue cells, including pancreatic β-cells as well as exocrine pancreatic cells [20,21]. It has been shown that SARS-CoV-2 infects [22] and replicates in pancreatic cells, thereby altering pancreatic β-cell function directly and impairing insulin secretion [23–25]. In addition, the novel coronavirus could trigger autoimmunity. Thus, both autoantibody-negative and autoantibody-positive insulin-dependent diabetes can occur during a SARS-CoV-2 infection. In the case of T2DM, social distancing with indoor stay, increased time out of school, consumption of high-calorie foods, isolation with further reduction in exercise, worsening of obesogenic factors in a genetically predisposed population, and health disparities with delayed seeking of health care may have all contributed towards a higher incidence as the pandemic progressed [26].

**T2DM and COVID-19:** This manuscript adds to the knowledge regarding the characteristics of T2DM in children with COVID-19 infection and demonstrate how this viral infection may worsen the already dysregulated glucose metabolism [27] with 3 of 7 children presenting with an increased insulin requirement.

When the children with T1DM are compared to those with T2DM, the elevated BMI in the T2DM group is apparent. Obesity is a well-established risk factor for T2DM. A variety of social and environmental risk factors had led to increased BMI during the observational time frame – lack of school, increased sedentary lifestyle, chronic stress and increased caloric intake, reduced availability and access to sports and activities that would have been otherwise expected in summer months, increased social isolation and food insecurity. A recent data analysis from the Centers for Disease Control showed that the rate of BMI increase approximately doubled during the pandemic compared to a prepandemic period among children and adolescents [28].

**DKA and COVID-19:** Eighteen (64.3%) of the 28 children presented in DKA of varying severity, 10 (55.6%) of whom were Black. This is perhaps reflective of health disparities, as they are becoming increasingly recognized [29]. The 12 children with pre-existing T1DM had uncontrolled diabetes with markedly elevated HbA1C before hospital admission. This observation is analogous to the reports from adults with diabetes in whom poor glycemic control is a risk factor for adverse metabolic outcomes [30]. A similar observation was also noted in the preliminary reports from the T1D Exchange [11].

The limitations of our study include a small sample size at a single center. We are also unable to capture the number of known persons with diabetes with COVID-19 who did not require hospitalization. The serum antibodies targeted against SARS-CoV-2 were not evaluated for any of these patients and in the overall group of hospitalized children with diabetes to identify a recent/past infection. Thus, we are unable to establish the association between recent SARS-CoV-2 infection and increased cases of new-onset diabetes in our patient population. However, with PCR positivity upon admission, it is likely that these children were acutely infected with SARS-CoV-2. Our review of data was also relatively limited, comparing 2020 to a similar time frame in the prior 2 years. Therefore, larger prospective studies are needed to better delineate the change in trends over time and understand the longitudinal impact on overall incidence.

In conclusion, this report highlights the importance of testing all children presenting with new-onset diabetes or DKA for COVID-19. In addition, this report also raises the need for further research into the relationship between SARS-CoV-2 and diabetes and why some children...
with diabetes and COVID-19 experience serious life-threatening complications. Furthermore, the influence of the ongoing surge driven by the Delta variant of SARS-CoV-2 on diabetes in children, especially in the southern U.S. with a higher proportion of infections in children and adolescents, needs to be examined.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors thank Eric Macomb (Pediatric Research Office) and Shunta Murry (Department of Pediatric Endocrinology) for their assistance with the data acquisition. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
[2] H. H, K. T. The role of viruses in human diabetes. Diabetologia 2002;45(10):1353–61.
[3] Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med. 1998;4(4):231–9.
[4] Hyoty H, Leinikki P, Reunanen A, Ilonen J, Surcel HM, Rilva A, et al. Mumps infections in the etiology of type 1 (insulin-dependent) diabetes. Diabetes Res. 1988;9(3):111–6.
[5] Pak C, Meahrur R, Eun H-M, Yoon J-W. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1988;332(8601):1–4.
[6] Kamrath C, Monkenmoller K, Bieter T, Rohrer TR, Warncke K, Hammeren M, et al. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. JAMA 2020;324(8):801. https://doi.org/10.1001/jama.2020.13445.
[7] Cardona-Hernandez R, Cherubini V, Iafusco D, Schiaffini R, Luo X, Maahs DM. Children and youth with diabetes are not at increased risk for hospitalization due to COVID-19. Pediatr Diabetes 2020. Epub 2020 Nov 26.
[8] Dayal D, Gupta S, Raihatha D, Jayashree M. Missing during COVID-19 lockdown: children with onset of type 1 diabetes. Acta Paediatr. 2020;109(10):2144–6.
[9] Pinnini S, Trieu C, Pati SK, Lattling M, Selemne MC, et al. Comparing nanopharyngeal and midturbinate nasal swab testing for the identification of severe acute respiratory syndrome coronavirus 2. Clin Infect Dis. Epub 2020 Jun 29.
[10] Charalampopoulos D, Hermann JM, Svensson J, Skrivarhaug T, Maahs DM, Akesson K, et al. Exploring variation in glycemic control across and within eight high-income countries: a cross-sectional analysis of 64,666 children and adolescents with type 1 diabetes. Diabetes Care 2018;41(6):1180–7.
[11] Ebeokezie OA, Noor N, Gallagher MP, Alonso GT, Type 1 diabetes and COVID-19: preliminary findings from a multicenter surveillance study in the U.S. Diabetes Care 2020;43(8):e83–5.
[12] Alonso GT, Ebeokezie O, Gallagher M, et al. Diabetic ketoacidosis drives COVID-19 related hospitalized children in type 1 diabetes. Diabetes Care 2021;1–7.
[13] Sellers EAC, Paucau D, on behalf of CAPACITY (Canadian Pediatric diabetes Consortium). Diabetic ketoacidosis at presentation of type 1 diabetes in children in Canada during the COVID-19 pandemic. Paediatrics & Child Health. 2021;1:2–7.
[14] Unsworth R, Wallace S, Oliver NS, Yeung S, Kohiragar A, Naidu H, et al. New-onset Type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care. 2020. Epub 2020 Aug 17.

[15] Rabbone I, Schiaffini R, Cherubini V, Maffeis C, Scaramuzza A. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? Diabetes Care 2020. Epub 2020 Aug 11.

[16] Kamrath C, Rosenbauer J, Eckert AJ, et al. Incidence of COVID-19 and risk of diabetic ketoacidosis in new-onset type 1 diabetes. Pediatrics 2021. https://doi.org/10.1542/peds.2021-050856.

[17] Divers J, Mayer-Davis EJ, Lawrence JM, Isom S, Dabelea D, Dolan L, et al. Trends in incidence of type 1 and type 2 diabetes among youths – selected counties and Indian reservations, United States, 2002–2015. MMWR Morb Mortal Wkly Rep 2020;69(6):161–7.

[18] Tuomilehto J, Ogle GD, Lund-Blix NA, Stene LC. Update on worldwide trends in occurrence of childhood type 1 diabetes in 2020. Pediatr Endocrinol Rev. 2020;17 (1):198–209.

[19] Dabelea D, Rewers A, Stafford JM, Standiford DA, Lawrence JM, Saydah S, et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics 2014;133(4):e938–45.

[20] Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7.

[21] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–80.

[22] Teng X, Uhl S, Zhang T, Xue D, Li Bo, Vaidana JJ, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab 2021;33(8):1577–1591.e7.

[23] Müller JA, Groli R, Conzelmann C, Krüger J, Merle U, Steinhart J, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3(2):149–65.

[24] Hollstein T, Schulte DM, Schulz J, Glück A, Ziegler AG, Bonifacio E, et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. Nat Metab. 2020;2(10):1021–4. https://doi.org/10.1038/s42255-020-0021-8.

[25] Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47(3):193–9.

[26] Rundle AG, Park Y, Herbstman JB, Kinsey EW, Wang YC. COVID-19-Related School Closings and Risk of Weight Gain Among Children. Obesity. 2020;28(6):1008–9.

[27] Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-onset diabetes in Covid-19. N Engl J Med. 2020;383(9):789–90.

[28] Lange SJ, Kompaniyets L, Freedman DS, Kraus EM, Porter R, Blanck HM, et al. Longitudinal trends in body mass index before and during the COVID-19 pandemic among persons aged 2–19 years – United States, 2018-2020. Morbidity and Mortality Weekly Report (MMWR), CDC. Published September 17, 2021. Updated September 23, 2021. Accessed October 10, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a3.htm?s_cid=mm7037a3_w.

[29] Ebekozien O, Agarwal S, Noor N, O Neill AA, Wong JC, Seeharanvong T, et al. Full inequities in diabetic ketoacidosis among patients with type 1 diabetes and COVID-19: data from 52 US clinical centers. J Clin Endocrinol Metab. Epub 2021 Jan 7.

[30] Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care 2018;41(10):2127–35.